Tag: anticoagulation
Factor XI inhibitor ‘lives up to promise’ of reduced bleeding events...
Researchers from Mass General Brigham (Boston, USA) have evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients...
Pivotal trial of dissolving film oral anticoagulant reaches completion
Taho Pharmaceuticals has announced the completion of the pivotal trial for TAH3311, an anticoagulant oral dissolving film (ODF).
The trial was conducted following detailed discussions...
AHA 2024: Blood thinners fail to reduce cognitive decline in younger...
Prescribing anticoagulation medications to adults younger than 65 years of age who have atrial fibrillation (AF) but no other risk factors for stroke does not...
AHA 2024: OPTION trial reports positive outcomes for Watchman FLX at...
Three-year results from the OPTION clinical trial, comparing the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) system to oral anticoagulation for stroke...
Apixaban associated with lower risk of gastrointestinal bleeding in AF patients...
Use of apixaban was associated with a lower risk of gastrointestinal bleed and similar rates of ischaemic stroke or systemic embolism, intracranial haemorrhage and...
Portola Pharmaceuticals unveils data on Andexxa in patients with multiple types...
Portola Pharmaceuticals announced new data that they say reinforces the value of Andexxa (coagulation factor Xa , inactivated-zhzo). The company statement outlines that the...
Patients with atrial fibrillation who are frail or have cognitive impairment...
Malini Madhavan (Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA) and others reported the results of a study in American Heart Journal that found...
Re-evaluate use of anticoagulation in patients with atrial flutter
A new study, published in JAMA Network Open, indicates that patients with atrial flutter have a lower incidence of stroke than patients with atrial...
ACC 2017: Uninterrupted dabigatran performs better than warfarin in atrial fibrillation...
Results from the RE-CIRCUIT study have shown that uninterrupted dabigatran (Pradaxa, Boehringer Ingelheim), was associated with fewer bleeding complications than uninterrupted warfarin before, during...
AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients...
Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily dose of the drug and a P2Y12 inhibitor and...
ESC 2016: Edoxaban is safe and effective in AF patients undergoing...
ENSURE-AF, the largest prospective, randomised clinical trial to date of anticoagulation for electrical cardioversion in non-valvular atrial fibrillation, has shown that edoxaban is an...